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Background: Selection of heath-related quality of life (HRQL) instruments that are
most responsive to changes in HRQL prevents investigators from drawing false-
negative conclusions about the effectiveness of an intervention. The objective of
this study was to compare the responsiveness of the Chronic Respiratory
Questionnaire (CRQ), the St. Georges Respiratory Questionnaire (SGRQ) and four
other HRQL instruments.Elsevier Ltd. All rights reserved.
earch Development and Information Translation Unit, Italian National Cancer Institute Regina
02.
r.ca (H.J. Schu¨nemann).
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ResponsivenessMethods: We enrolled 177 patients with chronic lung disease, primarily COPD (93%),
who completed 8 weeks of respiratory rehabilitation. Patients completed the CRQ,
the SGRQ and four generic measures (SF-36, Feeling Thermometer, Standard Gamble
and Health Utilities index 3) at the beginning of the rehabilitation program and 12
weeks thereafter. We calculated standardized response means (SRMs) for each
instrument, from the change score divided by the standard deviation of the change
score.
Results: We observed the largest SRM for the CRQ (0.24–0.66 for the four CRQ
domains on the interviewer-administered and 0.56–0.84 for the self-administered
format) and the SGRQ (0.33–0.51 for the three SGRQ domains and total score). The
CRQ dyspnea domain was statistically signiﬁcantly more responsive than any other
instrument including the SGRQ. For the SGRQ, the total and impacts domain were
signiﬁcantly more responsive than the generic and preference-based instruments.
Conclusions: This study conﬁrms that the CRQ and SGRQ are substantially more
responsive than generic measures, and suggests particularly strong responsiveness
for the self-administered CRQ.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Clinicians and investigators recognize the impor-
tance of measuring health-related quality of life
(HRQL) as a patient-important outcome in clinical
trials of patients with chronic obstructive pulmonary
disease (COPD) and other chronic lung disease.1–9
Because there is no single gold standard for the
measurement of HRQL, investigators need to select
instruments that meet their research goal. If change
in HRQL is the outcome of interest, as it is in the
evaluation of treatments, responsiveness is a key
measurement property. Responsiveness refers to an
instrument’s ability to detect HRQL change, even if
the magnitude of change is small.10 If instruments
are not responsive, investigators and clinicians could
draw false-negative conclusions from results of
clinical research and monitoring of health programs,
including respiratory rehabilitation.11
A number of validated HRQL instruments for
patients with chronic lung disease exist and
investigators often encounter challenges in select-
ing the optimal instrument. In general, disease-
speciﬁc instruments such as the Chronic Respiratory
Questionnaire (CRQ)12 are more responsive than
generic instruments such as the Sickness Impact
Proﬁle or SF-36. Indeed, earlier studies with COPD
patients indicated superior responsiveness of dis-
ease-speciﬁc instruments.11,13,14 Thus, when re-
sponsiveness is key, investigators need to choose
among disease-speciﬁc instruments such as the
widely used CRQ and St. George Respiratory
Questionnaire (SQRQ).15
A previous study with COPD patients following
respiratory rehabilitation found larger effect sizes
for the CRQ,14 while another study assessing the
effects of salmeterol and ipratropium bromide didnot clearly favour the CRQ or SQRQ in terms of
responsiveness.16 However, the latter study used a
non-validated self-administered CRQ version. We
recently validated a self-administered and standar-
dized version of the original CRQ17–19 that facilitates
the administration of the CRQ in a clinical trial or
practice setting. Investigators have not yet com-
pared this version of the CRQ with the SGRQ.
Other outcomes have attained greater interest in
clinical trials. For example, the comparison of
clinical interventions across patient groups or
evaluation of costs require generic HRQL instru-
ments and preference-based measures such as the
Feeling Thermometer (FT), Standard Gamble (SG),
or Health Utilities Index 3 (HUI3).20 Preference-
based instruments yield a single score between 0
and 1.0 and, in theory, allow comparison across
different health programs and interventions.21–24 In
addition, preference-based instruments are in-
creasingly used as global measures of HRQL in trials
so that responsiveness becomes important for these
instruments as well. Indeed scores obtained with
generic HRQL instruments have experienced trans-
formation into utility scores because of the
importance of a common metric that attempts to
measure both HRQL and utilities. However, data
addressing the responsiveness of preference-based
instruments in relation to other HRQL tools are so
far limited.25,26
The aim of this study was to compare the
responsiveness of the CRQ and other disease-
speciﬁc, generic and preference-based instruments
in patients with chronic lung disease following a
respiratory rehabilitation program. There is strong
evidence from meta-analyses that respiratory
rehabilitation leads to patient-important improve-
ments in HRQL among COPD patients.27 Therefore,
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for testing instrument responsiveness.Methods
Patients and study design
For this analysis, we used data from a multicentre
randomized trial that compared the measurement
properties of the interviewer- (CRQ-IA) and self-
administered CRQ (CRQ-SA) as well as those of
individual and standardized dyspnea questions.19 In
brief, we recruited patients with chronic lung
diseases (mainly COPD) at four University respira-
tory rehabilitation programs in Toronto, Ottawa,
Hamilton (all Canada) and Buffalo, NY (USA), and
randomly assigned them to a group with inter-
viewer- or self-administration of the CRQ. Patients
followed an outpatient respiratory rehabilitation
program of 8 weeks duration with an emphasis on
physical exercise. Patients completed all outcome
measures at the beginning of respiratory rehabili-
tation and approximately 12 weeks thereafter. We
previously described that we randomized 281
patients to receive either the CRQ-IA or CRQ-SA,19
of whom we excluded two before the baseline
assessment (inability to read) and of whom 102 did
not complete the study for the following reasons:
too much work or no time (n ¼ 25), too sick to
complete rehabilitation program (n ¼ 21), SARS
outbreak in Toronto (n ¼ 17), not available for
outcome assessment (n ¼ 14), not satisﬁed with
the rehabilitation program (n ¼ 12), death of
patients (n ¼ 7), death of one site investigator
(n ¼ 3) or move to another place (n ¼ 3). The
administration of the HRQL instruments was iden-
tical for all instruments with the exception of the
CRQ (administered as CRQ-IA and CRQ-SA) and the
FT (administered with or without prior rating of 3
hypothetical health states) and is described below.
Disease-speciﬁc instruments
Chronic Respiratory Questionnaire12
The original, interviewer administered CRQ has 20
items asking about the level of impairment in the
domains of dyspnea, fatigue, emotional function
and mastery. Patients express their degree of
impairment from 1 (most severe impairment) to 7
(no impairment). In the present study, we rando-
mized patients to complete either the original
interviewer-administered or the self-administered
version of the CRQ. All patients completed the
original individualized12 and, in addition, thestandardized17 dyspnea domain. We randomized
the mode of administration and the order of
individualized and standardized dyspnea questions
to prevent order effects. The CRQ served as a
model for many methodological studies13,19,28 and
has shown good measurement properties including
the self-administered format and the standardized
dyspnea questions.17–19
St. George’s Respiratory Questionnaire29
The self-administered SGRQ consists of 76 items
addressing the effect of respiratory disease on
HRQL. A total score and three domain scores for
symptoms, activity and impact summarize the
responses and range from 0% (best) to 100% (worst).
Previous studies showed good reliability, cross-
sectional and longitudinal validity of the SGRQ.13–15
Generic instruments
The Medical Outcomes Short Form 36 (SF-36)30: The
SF-36 consists of 8 domains including physical
functioning, role limitations-physical, bodily pain,
general health, vitality, social functioning, role
limitations-emotional, and mental health. The
domains scores can be aggregated into two compo-
site scores for physical and mental health. The SF-
36 scores range from 0 to 100, with higher scores
indicating better functioning and well-being. Both
composite scores are standardized to have a mean
score of 50 and standard deviation of 10 in the
general US population. The SF-36 is valid and
responsive to change in a variety of patient groups,
including patients with COPD.3
Preference-based instruments
Feeling Thermometer31
The FT is a visual analogue scale presented in the
form of a thermometer with 100 intervals, in which
the best state is full health (equal to a score of 100)
and the worst state is dead (a score of 0). We asked
patients to reﬂect the health status in their score
as it was during the last 7 days. We had adminis-
tered the FT with or without clinical marker
states.32 The latter occurred in random order in a
2 2 factorial design. The FT has demonstrated
good measurement properties in patients with
COPD.24,33
Standard Gamble31
The SG offers the patient two alternatives from
which a choice must be made: Choice A is a
hypothetical treatment with two possible out-
comes: (1) returning to full health (probability p)
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immediate death (probability 1P). The alterna-
tive (choice B) is the certain outcome that he/she
will stay in their own health state for t years until
death. The indifference probability, P*, is the utility
value for the health state in choice A in the interval
from dead ( ¼ 0) to full health ( ¼ 1). The greater a
respondent’s willingness to accept the risk of a
worse outcome (e.g. dead) to avoid the health
state in choice A, then the lower is the utility of the
state in choice A to them.Health Utilities Index 320
We used the self-administered Health Utilities Index
3 questionnaire with 15 items and asked patients to
recall their health status over the week prior to the
interview. The 8 attributes in the Health Utilities
Index 3 multi-attribute utility measure are vision,
hearing, speech, ambulation, dexterity, emotion,
cognition and pain. Each item has 5 or 6 response
options. Based on the questionnaire responses we
calculated a utility score from 0 to 1.0 where 0
represents dead and 1.0 full health.24Statistical analysis
To compare the responsiveness across instruments,
we calculated standardized response means (SRMs)
for each individual patient by dividing the change
scores of each instrument (follow-up minus base-
line score) by the standard deviations (SDs) of
change scores of the whole study group. We
compared SRMs among all instruments using paired
t-tests and calculated 95% conﬁdence intervals for
SRMs using the approach proposed by Beaton et
al.34 We performed all comparisons across instru-
ments within one group including all patients. For
the comparison of the SRMs, we combined both CRQ
(CRQ-IA and CRQ-SA) and both FT groups to
facilitate comparisons with the other HRQL instru-
ments because the SRMs did not differ signiﬁcantly
between the CRQ-IA and CRQ-SA and the FTwith or
without clinical marker states. The larger sample
size provided greater precision to estimate differ-
ences in relative responsiveness between the HRQL
instruments.
The SRM, a widely used measure for responsive-
ness,35 differs from change scores in that it is
corrected for the SD of the change score.34 We
chose SRMs because it removes dependency on
sample size as opposed to t-tests that depend on
sample size. The SRM is superior to Cohen’s effect
size (change scores divided by SDs of baseline
scores) because the signal (change score) relates
to the noise term (SD of change score) directly.Using the SD of the change scores in the SRM rather
than the SD of the baseline scores is an advantage
over Cohen’s effect size because baseline scores
may be unrelated to change score variability. We
performed the analyses using SAS 8.2 (SAS Institute
Inc., Cary, NC, USA).Results
Mean age of the 177 included patients was 69.0
years (SD 8.7), 59% were males, mean FEV1 was 42.8
(19.2) % predicted and the proportion of patients
with COPD was 93%. 7% of enrolled patients had
other chronic lung diseases including idiopathic
pulmonary ﬁbrosis, chronic pulmonary aspergillosis,
post-pulmonary resection and bronchiectasis.
Table 1 shows the SRMs of the disease-speciﬁc,
generic and preference-based instruments. In gen-
eral, SRMs were higher for the CRQ-SA compared to
the CRQ-IA. The disease-speciﬁc CRQ and SGRQ
showed larger SRMs compared to similar domains on
the generic and preference-based instruments.
However, the physical composite score of the SF-
36 showed similar responsiveness (SRM ¼ 0.37) was
similar to the fatigue, emotions and mastery
domains of the CRQ-IA and the activities and
impact domain on the SGRQ. The CRQ dyspnea
domains tended to have larger SRMs compared to
the CRQ fatigue, emotions and mastery domains.
The SGRQ total score showed a larger SRM than the
SGRQ domains scores. While the signal of the SGRQ
total score (mean change score of 5.4) was similar
compared to the signal on the three domains
(4.7–6.2), the standard deviation of change scores
was lower (11.2 for total score versus 15.4 for the
activities, 12.5 for the impacts and 17.6 for the
symptoms domain).
Table 2 shows the comparisons of SRMs across
instruments. The individualized dyspnea domain of
the CRQ showed signiﬁcantly higher responsiveness
that all other instruments while the standardized
dyspnea domain was signiﬁcantly more responsive
than the generic and preference-based instruments
and the SGRQ domains. The mastery domain of the
CRQ was more responsive compared to the generic
and preference-based instruments, but did not
differ from the SGRQ total and impacts score. The
CRQ fatigue and emotions domain were signiﬁ-
cantly more responsive than the SF-36 mental
composite score and the Health Utilities Index 3.
The SGRQ total score was signiﬁcantly more
responsive than the generic and preference-based
instruments. However, only the impacts domain
was signiﬁcantly more responsive than the generic
and preference-based instruments.
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Table 1 Standardized response means of disease-speciﬁc, generic and preference-based instruments in
patients with COPD after respiratory rehabilitation.
Instrument Standardized response mean (95%
conﬁdence interval)
Disease-speciﬁc instruments
CRQ-IA (n ¼ 86)
Dyspnea (Individualized) 0.66 (0.45, 0.87)
Dyspnea (Standardized) 0.50 (0.29, 0.71)
Fatigue 0.25 (0.04, 0.46)
Emotional function 0.24 (0.03, 0.45)
Mastery 0.38 (0.17, 0.59)
CRQ-SA (n ¼ 91)
Dyspnea (Individualized) 0.84 (0.63, 1.05)
Dyspnea (Standardized) 0.69 (0.48, 0.90)
Fatigue 0.60 (0.39, 0.81)
Emotional function 0.56 (0.35, 0.77)
Mastery 0.70 (0.49, 0.91)
SGRQ (n ¼ 177)
Total Score 0.51 (0.36, 0.66)
Activities 0.33 (0.18, 0.48)
Impacts 0.46 (0.31, 0.61)
Symptoms 0.34 (0.19, 0.49)
Generic instrument
SF-36 (n ¼ 177)
Physical composite score 0.37 (0.22, 0.52)
Mental composite score 0.17 (0.02, 0.32)
Physical functioning domain 0.30 (0.15, 0.45)
Role physical domain 0.21 (0.06, 0.36)
Bodily pain domain 0.22 (0.07, 0.37)
General health domain 0.20 (0.06, 0.35)
Vitality domain 0.37 (0.22, 0.52)
Social functioning domain 0.21 (0.06, 0.36)
Role emotional domain 0.07 (-0.08, 0.22)
Mental health domain 0.15 (0.002, 0.30)
Preference-based instruments
Feeling Thermometer (n ¼ 177) 0.28 (0.13, 0.43)
Standard Gamble (n ¼ 177) 0.21 (0.06, 0.36)
Health Utilities Index 3 (n ¼ 177) 0.20 (0.05, 0.35)
M.A. Puhan et al.312Among the generic and preference-based instru-
ments, the SF-36 physical composite score was
most responsive, but the differences with other
instruments did not reach statistical signiﬁcance.
The FTshowed a larger SRM compared to the SG and
Health Utilities Index 3, but these differences were
not statistically signiﬁcant.Discussion
This comparison of six HRQL and preference-based
instruments showed that the self-administered
CRQ, in particular the individualized and standar-
dized dyspnea domains, are most responsive tochanges in patients with chronic lung disease
undergoing respiratory rehabilitation. The generic
and preference-based instruments showed inferior
relative responsiveness and did not differ signiﬁ-
cantly from each other.
Strengths of this study include the standardized
administration or supervision of instruments by
trained interviewers present in all centers. In
addition we included a battery of the most widely
used disease-speciﬁc, generic and preference-
based instruments available for patients with
chronic lung disease and randomized the order of
administration for the individualized and standar-
dized CRQ dyspnea domains to eliminate order
effects.
ARTICLE IN PRESS
Ta
b
le
2
C
om
p
ar
is
on
of
st
an
d
ar
d
iz
ed
re
sp
on
se
m
ea
ns
(n
¼1
77
).
C
R
Q
d
ys
p
ne
a
(i
nd
iv
id
ua
li
ze
d
)
C
R
Q
d
ys
p
ne
a
(s
ta
nd
ar
d
iz
ed
)
C
R
Q
fa
ti
gu
e
C
R
Q
em
ot
io
ns
C
R
Q
m
as
te
ry
SQ
R
Q
to
ta
l
sc
or
e
SQ
R
Q
ac
ti
vi
ti
es
SQ
R
Q
im
p
ac
ts
SQ
R
Q
sy
m
p
to
m
s
SF
36
-
p
hy
si
ca
l
SF
36
-
m
en
ta
l
Fe
el
in
g
T
he
rm
o-
m
et
er
St
an
d
ar
d
G
am
b
le
SQ
R
Q
to
ta
l
sc
or
e
0
.2
7

0.
12
0
.0
7
0
.0
9
0.
06
SQ
R
Q
ac
ti
vi
ti
es
0
.4
5

0
.3
0

0.
11
0.
09
0
.2
4

SQ
R
Q
im
p
ac
ts
0
.3
0

0
.1
5

0
.0
3
0
.0
5
0.
10
SQ
R
Q
sy
m
p
to
m
s
0
.4
1

0
.2
6

0.
07
0.
05
0
.2
0

SF
36
-p
hy
si
ca
l
0
.4
0

0
.2
6

0.
07
0.
06
0
.2
1

0
.1
5

0
.0
4
0.
11
0
.0
1
SF
36
-m
en
ta
l
0
.6
1

0
.4
7

0
.2
8

0
.2
7

0
.4
2

0
.3
6

0.
17
0
.3
2

0
.2
0

Fe
el
in
g
T
he
rm
om
et
er
0
.4
7

0
.3
2

0.
13
0.
12
0
.2
6

0
.2
0

0.
02
0.
17
0.
06
0.
06
0
.1
5
St
an
d
ar
d
G
am
b
le
0
.5
4

0
.3
9

0
.2
1

0.
19
0
.3
3

0
.2
8

0.
10
0.
24

0.
14
0.
13
0
.1
0
0.
05
H
ea
lt
h
U
ti
li
ti
es
In
d
ex
3
0
.5
5

0
.4
0

0
.2
2

0
.2
1

0
.3
6

0
.2
7

0.
08
0
.2
5

0.
15
0.
12
0
.0
8
0.
08
0.
00
2
D
if
fe
re
nc
es
in
st
an
d
ar
d
iz
ed
re
sp
on
se
m
ea
ns
b
et
w
ee
n
va
ri
ab
le
s
in
co
lu
m
ns
an
d
ro
w
s
(p
os
it
iv
e
sc
or
es
in
d
ic
at
in
g
hi
gh
er
SR
M
in
co
lu
m
ns
)

D
if
fe
re
nc
es
si
gn
iﬁ
ca
nt
at
Pp
0:
05
.

D
if
fe
re
nc
es
si
gn
iﬁ
ca
nt
at
Pp
0:
01
.
Comparison of six HRQL and preference-based instruments 313A recent systematic review comparing the
responsiveness of speciﬁc and generic HRQL instru-
ments in RCTs showed superior responsiveness of
speciﬁc instruments across a wide range of patients
and interventions.36 To appraise studies that
included comparisons of responsiveness between
speciﬁc, generic and preference-based instruments
in COPD patients (on which our study focused), we
performed a PubMed search. We used the following
terms ‘‘QUALITY OF LIFE [MESH]’’, ‘‘instrument* OR
scale* OR tool* or questionnaire*’’, ‘‘COMPARATIVE
STUDY [MESH]’’ and ‘‘Lung Diseases, Obstructive
[MESH] OR COPD [MESH]’’. Of 119 potentially
relevant articles, 14 reported on comparisons of
relative responsiveness.11,14,16,25,26,37–45 The ma-
jority of studies reported superior responsiveness
of disease-speciﬁc instruments (CRQ, SGRQ, Re-
spiratory Quality of Life Questionnaire and Pulmon-
ary Functional Status Instrument) compared to
generic instruments (SF-36, Sickness Impact Proﬁle,
Nottingham Health Proﬁle, Quality of Well
Being),11,37,38,42–45 while two studies did not ﬁnd
differences.14,41 One study found superior respon-
siveness of the Nottingham Health Proﬁle compared
to the SGRQ.39 Two studies14,38 comparing the CRQ
and SGRQ concluded that the CRQ is more
responsive, while two other studies16,40 did not
favour one over the other instrument in terms of
responsiveness.
However, only one study formally compared
responsiveness within patients across instruments11
while most studies assessed responsiveness for
each instrument separately. For example, the
studies assessed whether the difference between
baseline and follow-up scores was statistically
signiﬁcant for each instrument using one-sample
t-tests14,16,25,26,38,40,45 and declared similar respon-
siveness when instruments detected signiﬁcant
differences. Other studies used Cohen’s effect
sizes14 or SRMs11. Only one study used, in addition
to t-tests, the minimal important difference to
deﬁne responsiveness as the ability of an instru-
ment to detect patient-important changes.16
Consensus does not exist about the most appro-
priate method to assess and compare responsive-
ness.46,47 Unlike most earlier studies, we did not
rely on t-tests14,16,25,26,38,40,45 or Cohen’s effect
sizes14 to assess and compare responsiveness.
Signiﬁcance testing using t-tests depends partly
on the observed change scores and variability in
change scores. However, this test also depends on
sample size, which should not inﬂuence judgments
about responsiveness.46,48 Cohen’s effect size is
calculated by dividing the change score by the
standard deviation of the baseline score. In
contrast to variability in change, there is no
ARTICLE IN PRESS
M.A. Puhan et al.314necessary or logical relationship between between-
person variability at baseline and instrument
responsiveness. We used the SRM to compare
responsiveness within patients across several in-
struments, because the SRM deals with the afore-
mentioned limitations in that the denominator
captures variability in change (the noise component
of the signal-to-noise ratio) and removes the
dependency on sample size.46,49,50 However, the
multiple comparison we used in this analysis do
raise the possibility of a type I error. One solution to
this problem is reliance on lower P-values and
readers may focus on the P-values that are less than
0.01 in our analysis. Other methods of correction
for multiple testing have limitations because the
comparison we conducted were not independent.
The superior responsiveness of the SGRQ total
score compared to its domain scores deserves
attention. The increased number of items in the
total score resulted in decreased variability in
change, and thus an increased signal (change score)
to noise (SD of change scores) ratio. Thus by
calculating total scores, the SRM becomes larger
compared to the domain scores. There are, how-
ever, limitations to using a total score. If effects of
an intervention vary across domains of HRQL, the
total score obscures potentially important informa-
tion from HRQL domains and may result in
misleading interpretations. In the present study,
the effect of respiratory rehabilitation was similar
in all domains and the SGRQ total score may
adequately represent the overall treatment effect.
In the present article, we did not calculate CRQ
total scores because use of CRQ total scores
requires additional research.
Investigators should not base the selection of the
instrument on responsiveness alone, but also on
longitudinal validity. In order to understand if an
instrument measures changes in HRQL that one
intends to measure, one needs to consider correla-
tions of change scores with those of other instru-
ments. We have previously described the
longitudinal construct validity for the CRQ-IA and
CRQ-SA and SGRQ.19 The results of the latter and
other studies suggest that the CRQ and SGRQ
measure similar constructs.13,14,17,28
In recent years, investigators suggested that
HQRL instruments can be used in clinical practice
for evaluation purposes but also to facilitate the
discussion of HQRL issues between patients and
clinicians.51 Clinicians should also choose instru-
ments based on evidence about the measurement
properties. But there are practical aspects that are
important for a successful introduction of HQRL
instruments into clinical practice. First, the dura-
tion and mode of administration (interviewerversus self-administration) should require as few
resources as possible. Second, calculation of
domain or summary scores should be straightfor-
ward and not involve complicated algorithms.
Third, there should be evidence about the minimal
important difference to guide interpretation of
domain or summary scores. Considering these
practical aspects, the CRQ-SA is likely to be the
most prudent choice as a HQRL instrument for
clinical practice.
This study conﬁrms that the disease-speciﬁc
HRQL instruments (CRQ and SGRQ), in particular
the CRQ dyspnea domain, are substantially more
responsive than generic measures when used for
the evaluation of respiratory rehabilitation. It is
possible that the relative responsiveness of HRQL
instruments may depend on the population studied
and contexts other than respiratory rehabilita-
tion.48 Studies using fully validated instruments
evaluating the extent to which responsiveness
depends on patients or interventions would en-
hance our understanding of the measurement of
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